35 C
Sunday, May 24, 2020

Covid 19 brought sudden change in the medication needs of people

COVID-19: India bans export of wonder drug - HydroxychloroquineNew Delhi, April 18 (IANS) The novel coronavirus pandemic has brought about a sudden change in the medication needs of masses with a clear preference being shown for respiratory, anti-diabetic, cardiac therapies as compared to anti-infective, gastro, vitamin or pain therapies that had commanded higher demand in pre-Covid period.

In the month of March, demand for Cardiac drugs grew by 18.8 per cent yoy and Anti-Diabetic segment grew at 14.4 per cent yoy due to pre-empted buying ahead of the lockdown. Similarly, the Respiratory segment (+26 per cent yoy) saw higher demand due to Covid-19 as the virus is known to impact this critical function of the human body.

- Advertisement -

Segments like Derma/Gynaec/Vitamins, where the demand for drugs has always remained ahead of others declined year-on-year in March, clearly bringing out the shift in drug use by Indians, especially during the time of lockdown.

According to a Emkay research report, the changing preference of drugs by people has also had an impact on the Indian pharmaceutical industry with companies having stronger drug brands dealing with respiratory, cardiac and anti-diabetic therapies registering growth higher than the industry average.

Accordingly, while Carols Healthcare, Dr Reddy”s Labs, Alkem having higher drug concentration in acute exposure category underperformed the Indian Pharmaceutical Market (IPM), Sun Pharma, Torrent Pharma, Lupin outperformed the market due to their high chronic portfolio.

Cipla, Glenmark outperformed due to strong respiratory demand, while IPCA benefitted from high hydroxychloroquine sales, which has been touted as wonder drug having potential to positively impact severe Covid-19 patients.

The brokerage report said that the Indian pharmaceutical market (IPM) growth slowed down to 5.4 per cent yoy in March 2020 as companies with acute-heavy portfolios reported weak growth on account of the countrywide lockdown. Volume growth was flat at 0.6 per cent yoy. On Moving average total basis, IPM growth stands at 10.8 per cent yoy, led by price hikes of 5.1 per cent.


Total Cases

Active Cases







Covid 2019 India Stats Overview. Source: Ministry of Health and Family Welfare. Updated: 24 May 2020, 08:00


Please enter your comment!
Please enter your name here

Must Read

Some airlines start to accept bookings for June onwards travel: Sources

New Delhi, May 20 (IANS) The COVID-19 battered airline industry has started accepting ticket bookings for the travel period...

Decision soon on film shootings, screenings: Kishan Reddy

Hyderabad, May 24 (IANS) Amid the gradual relaxation of lockdown regulations in all sectors, Union Minister of State for Home Affairs G. Kishan Reddy...

BCCI is ready for ‘cloded door games’ says says fans’ safety priority

New Delhi, May 24 (IANS) Union Sports Minister Kiren Rijiju has made it clear that under present circumstances, the country should be ready for...

India might allow int”l flights ops from July: Minister

New Delhi, May 24 (IANS) International flight operations from India might commence from July depending upon the circumstances surrounding the Covid-19 outbreak, Union Civil...

ICMR revises guidelines for use of Hydroxychloroquine

New Delhi, May 24 (IANS) The Indian Council of Medical Research (ICMR) has issued revised guidelines for use of hydroxychloroquine (HCQ), the malaria drug,...

More Articles Like This